Research Programs

The CombinatoRx preclinical pipeline includes multiple drug candidates targeted for potential development in multiple immuno-inflammatory diseases, oncology, neurodegenerative diseases, infectious diseases and other therapeutic areas.

Ion Channel Programs

N- and T-type compounds derive from a rational drug design process that has successfully led to the discovery of high affinity, selective and orally available calcium channel blockers. Distinguishing itself from its competitors, which rely on more standard approaches such as mass screening, we use electrophysiological screening in our evaluation process. Electrophysiology allows us to develop state and frequency dependant blockers. It is anticipated that by improving the selectivity of the N-type block in this way compounds with excellent safety and tolerability profiles can be developed.

B-cell Malignancies

The synergy we have seen with this novel, multi-target mechanism combination is very robust. It acts across multiple models of B-cell malignancies such as multiple myeloma, and importantly, is also synergistic with standard-of-care therapies. The compounds in this combination are not approved drugs, but they have previously been tested in humans. Again, taking advantage of the CombinatoRx business model, we are able to use their known human pharmacology to identify the novel biology this combination creates.

Novartis

Collaboration with Novartis focused on the discovery of novel anti-cancer combination.

Biodefense

Potential therapeutics for anthrax toxin through grant from National Institute of Allergy and Infectious Disease (NIAID).

Grant from US Army Medical Research Institute for Infectious Diseases (USAMRIID) for research and development of potential treatments for viral hemorrhagic fevers.

Ophthalmic Disease

Collaboration with Fovea Pharmaceuticals SA to develop novel treatments for ophthalmic diseases.